Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal?

S Gulstene; T Ruwanpura; D Palma; N Joseph

doi:10.1016/j.clon.2022.08.027

Stereotactic Ablative Radiotherapy in the Treatment of Early-Stage Lung Cancer - A Done Deal?

Clin Oncol (R Coll Radiol). 2022 Nov;34(11):733-740. doi: 10.1016/j.clon.2022.08.027. Epub 2022 Aug 30.

Authors

S Gulstene¹, T Ruwanpura², D Palma¹, N Joseph³

Affiliations

¹ Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada.
² The Christie NHS Foundation Trust, Manchester, UK.
³ The Ministry of Health, Colombo, Sri Lanka. Electronic address: [email protected].

PMID: 36050221
DOI: 10.1016/j.clon.2022.08.027

Abstract

Stereotactic ablative radiotherapy (SABR) is an important curative-intent treatment option for early-stage non-small cell lung cancer. It offers good cancer control without invasive surgery and has become the standard of care for medically inoperable patients. The literature on SABR for early-stage non-small cell lung cancer is substantial and continues to grow. However, there remain areas of controversy where data are limited - notably the use of SABR in medically operable patients. Other areas of some debate include the treatment of central/ultra-central and large (>5 cm) lesions, as well as treatment with co-existing interstitial lung disease. This review article provides an overview of the current literature together with a discussion of future directions.

Keywords: Early-stage lung cancer; NSCLC; SABR; SBRT; lung cancer; non-small cell lung cancer.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / pathology
Carcinoma, Non-Small-Cell Lung* / radiotherapy
Carcinoma, Non-Small-Cell Lung* / surgery
Humans
Lung Neoplasms* / pathology
Lung Neoplasms* / radiotherapy
Lung Neoplasms* / surgery
Neoplasm Staging
Radiosurgery* / adverse effects
Small Cell Lung Carcinoma* / pathology
Treatment Outcome